Results 181 to 190 of about 12,467 (245)

Acute cholecystitis as an adverse effect of treatment with elexacaftor/tezacaftor/ivacaftor in a patient with cystic fibrosis

Carlos Martín de Vicente, Silvia Jade Cáceres Barrera, Sánchez González, Cristina Alonso, Ruth García Romero   +4 more
openalex   +1 more source

Top 10 drugs 2024-25. [PDF]

Aust Prescr
europepmc   +1 more source

Real-World Outcomes of Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis. [PDF]

Ann Am Thorac Soc
Perrem L, McNally P.
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis. [PDF]

Pediatr Pulmonol
Trost SU, Harindhanavudhi T, Wang Q, Ankireddypalli A, Simrah A, Avula S, Moheet A.   +6 more
europepmc   +1 more source

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study

Francesca Lucca, Ilaria Meneghelli, Gloria Tridello, Francesca Buniotto, Giulia Cucchetto, Sonia Volpi, Emily Pintani, Valentino Bezzerri, Marco Cipolli   +8 more
openalex   +2 more sources

Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis: No Longer "If" but a Question of "When" to Start. [PDF]

Am J Respir Crit Care Med
Selvadurai H.
europepmc   +1 more source

A systematic review and meta-analysis of the treatment modalities available for children afflicted from cystic fibrosis. [PDF]

BMC Pediatr
Alruwaili TAM, Alanazi MF, Alruwaili BF, Fayed HK, Elsaeed M, Alnazi TD, Aljared A, Alanazi AMW, Alanazi AM, Alsharari SD, Alshammari A, Saad K.   +11 more
europepmc   +1 more source

Dried Blood Spot Method Development and Clinical Validation for the Analysis of Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using LC-MS/MS

Steffie E. M. Vonk, Marloes van der Meer‐Vos, Renate Kos, Anne H. Neerincx, Suzanne W. J. Terheggen‐Lagro, Josje Altenburg, Anke H. Maitland‐van der Zee, Ron A. A. Mathôt, E. Marleen Kemper   +8 more
openalex   +1 more source

Real-World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study. [PDF]

Clin Transl Sci
Perrotta N, Fiorito LA, Gentile R, Vescovo R, Piciocchi A, Troiani P, Poscia R, Cimino G.   +7 more
europepmc   +1 more source

Delayed-onset drug-induced liver injury in a cystic fibrosis patient on long-term elexacaftor/ivacaftor/tezacaftor therapy: A case report and literature review. [PDF]

Can Liver J
Alenezi AF, Sachar Y, Sandhu A.
europepmc   +1 more source